Clinical trial · Interventional
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The recent data suggest that cancer cells at the origin of prostate cancer metastases can be detected in an early stage. Available techniques allow phenotypic analysis of cancer cells in circulating blood (cellsearch) or in marrow hematopoietic (flow cytometry). Pilot study on 180 patients infected by prostate cancer at all stage of disease, show that c-met marker , integrin alpha 2 and 6 expressed in marrow and quantified by flow cytometry were predictor of metastatic progress. In this new study the investigators will analyze antibody panel by cellsearch and flow cytometry on marrow sample of castration-Resistant prostate cancer patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bone marrow sampling | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- CellSearch
- interventionNames
- Biological: Bone marrow sampling
Primary outcomes (1)
- measure
- Risk of death according to positive makers
- timeFrame
- Two years
Secondary outcomes (3)
- measure
- Risk of clinical progression according to positive markers.
- timeFrame
- Two years
- measure
- Risk of biological progression according to positive markers.
- timeFrame
- Two years
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed adenocarcinoma or prostate * Ongoing effective androgen deprivation therapy (testosterone ≤ 50 ng/mL) * Castration-Resistant prostate cancer patient : defined as a minimum of 3 rising PSA values assessed and/or radiological progress confirmed by RECIST and PCWG2 * Patient who signed informed consent Exclusion Criteria: * Severe disorders of coagulation * Major skin lesion on iliac crests * Allergies in local anesthetics * Psychological instability or psychiatric histories * Uncertain follow-up and distant residence * History of another invasive cancer and hematologic disease * Patient deprived of their freedom by court or administrative order * Revocation of consent
References
Publications (0)
Data not yet available